Killing effect of the herpes simplex virus thymidine kinase/ganciclovir enzyme/prodrug system on human nasopharyngeal carcinoma cells

Journal of International Medical Research

Volumn 35, Issue 4, 2007, Pages 433-441

  Tang, Y ^a,c   Li, J ^a   Zhao, S ^a   Liu, J ^b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c NONE   (China)

Author keywords

Ganciclovir; Gene therapy; Herpes simplex virus thymidine kinase; Nasopharyngeal carcinoma cell line; Suicide gene

Indexed keywords

DRUG METABOLITE; GANCICLOVIR; MESSENGER RNA; PLASMID DNA; PLASMID VECTOR; THYMIDINE KINASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BYSTANDER EFFECT; CANCER CELL CULTURE; CANCER GENE THERAPY; CELL KILLING; COCULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG TRANSFORMATION; ELECTROPORATION; GENE AMPLIFICATION; GENE DIRECTED ENZYME PRODRUG THERAPY; GENE EXPRESSION; GENETIC TRANSFECTION; GROWTH INHIBITION; HERPES SIMPLEX; HUMAN; HUMAN CELL; MOLECULAR BIOLOGY; NASOPHARYNX CARCINOMA; NONHUMAN; SUICIDE GENE THERAPY; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS GENE; WESTERN BLOTTING; WILD TYPE;

EID: 34547915899     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000703500401     Document Type: Article

References (23)

1. Kuriyama S, Masui K, Sakamoto T, et al: Bystander effect caused by cytosine deaminase gene and 5-fluorocytosine in vitro is substantially mediated by generated 5-fluorouracil. Anticancer Res 1998; 18: 3399-3406.
2. Kaneko Y, Tsukamoto A: Gene therapy of hepatoma: bystander effects and non-apoptotic cell death induced by thymidine kinase and ganciclovir. Cancer Lett 1995; 96: 105-110.
3. Moolten FL, Wells JM, Heyman RA, et al: Lymphoma regression induced by ganciclovir in mice bearing a herpes thymidine kinase transgene. Hum Gene Ther 1990; 1: 125-134.
4. Hirayama T: Descriptive and analytical epidemiology of nasopharyngeal carcinoma cancer. IARC Sci Publ 1978; 20: 167-189.
5. Tang Y, Xu J, Liu I, et al: Study of treating laryngeal cancer with suicide fusion gene CDglyTK in vitro. Chin Modern Med J 2006; 16: 1766-1771.
6. Ye M, Xu G: Surgery of recurrent or residual nasopharyngeal carcinoma after radiotherapy. ZhongHuaErBiYanHouKeZaZhi 1989; 24: 234-235 (in Chinese).
7. Chen X, Chen C, Zhang H, et al: The discussion of re-radiotherapy on recurrence of nasopharyngeal carcinoma after radiotherapy. ZhongHuaZhongLiuZaZhi 1984; 6: 134-135 (in Chinese).
8. Wildner O, Blaese RM, Candotti F: Enzyme prodrug gene therapy: synergistic use of the herpes simplex virus-cellular thymidine kinase/ ganciclovir system and thymidylate synthase inhibitors for the treatment of colon cancer. Cancer Res 1999; 59:5233-5238.
9. Mizuno M, Ryuke Y, Yoshida J: Cationic liposomes conjugation to recombinant adenoviral vectors containing herpes simplex virus thymidine kinase gene followed by ganciclovir treatment reduces viral antigenicity and maintains antitumor activity in mouse experimental glioma models. Cancer Gene Ther 2002; 9: 825-829.
10. Sa Cunha A, Bonte E, Dubois S, et al: Inhibition of rat hepatocellular carcinoma tumor growth after multiple infusions of recombinant Ad. AFPtk followed by ganciclovir treatment. J Hepatol 2002; 37: 222-230.
11. Hsieh CL, Gardner TA, Miao L, et al: Cotargeting tumor and stroma in a novel chimeric tumor model involving the growth of both human prostate cancer and bone stromal cells. Cancer Gene Ther 2004; 11: 148-155.
12. Chow KP, Lu HC, Chou HF, et al: Induction of chemosensitivity in nasopharyngeal carcinoma cells using a human papillomavirus regulatory sequence and the thymidine kinase gene. J Biomed Sci 2002; 9: 41-46.
13. Germano IM, Fable J, Gultekin SH, et al: Adenovirus/herpes simplex-thymidine kinase/ganciclovir complex: preliminary results of a phase I trial in patients with recurrent malignant gliomas. J Neurooncol 2003; 65: 279-289.
14. Fogar P, Greco E, Basso D, et al: Suicide gene therapy with HSV-TK in pancreatic cancer has no effect in vivo in a mouse model. Eur J Surg Oncol 2003; 29: 721-730.
15. Muramatsu T, Mizutani Y, Ohmori Y, et al: Comparison of three nonviral transfection methods for foreign gene expression in early chicken embryos in ovo. Biochem Biophys Res Commun 1997; 230: 376-380.
16. Li Y, Chen Z: The transfected effect comparison between electroporation and lipofection on cancer of the cervix. Nanhua Med Bull 2006, 34: 526-529.
17. Okabe S, Arai T, Yamashita H, et al: Adenovirus-mediated prodrug-enzyme therapy for CEA-producing colorectal cancer cells. J Cancer Res Clin Oncol 2003; 129: 367-373.
18. Blaszczyk N, Masri BA, Mawji NR, et al: Osteoblast-derived factors induce androgen-independent proliferation and expression of prostate-specific antigen in human prostate cancer cells. Clin Cancer Res 2004; 10: 1860-1869.
19. Majumdar AS, Hughes DE, Lichtsteiner SP, et al: The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters. Gene Ther 2001; 8: 568-578.
20. Qiu Z, Harms JS, Zhu J, et al: Bovine herpesvirus tegument protein VP22 enhances thymidine kinase/ganciclovir suicide gene therapy for neuroblastomas compared to herpes simplex virus VP22. J Virol 2004; 78: 4224-4233.
21. Kong B, Wang W, Liu C, et al: Efficacy of lentivirus-mediated and MUC1 antibody-targeted VP22-TK/GCV suicide gene therapy for ovarian cancer. In Vivo 2003; 17: 153-156.
22. Liu CS, Kong B, Xia HH, et al: VP22 enhanced intercellular trafficking of HSV thymidine kinase reduced the level of ganciclovir needed to cause suicide cell death. J Gene Med 2001; 3: 145-152.
23. Dilber MS, Phelan A, Aints A, et al: Intercellular delivery of thymidine kinase prodrug activating enzyme by the herpes simplex virus protein, VP22. Gene Ther 1999; 6: 12-21.